Cancer Treatment
Research from Germany, Netherlands and Egypt add new data to cancer treatment body of knowledge
Published in Cancer Weekly, August 15th, 2006
Study 1: Repetitive high dose-chemotherapy with escalated CHOP plus etoposide is feasible and effective in patients with aggressive non-Hodgkin lymphoma.
According to recent research from Germany, "Feasibility, safety, and efficacy of a 4-course high-dose chemotherapy (HDT) protocol including autologous stem cell transplantation (SCT) after courses 2, 3, and 4 was investigated in 110 patients, aged 18 to 60 years, with primary diagnosis of aggressive NHL (aNHL), and lactic dehydrogenase (LDH) levels above normal.
"At dose level 1 (DL1), course...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-08-15)
More Articles from Cancer Weekly
- Breast Cancer
Breast cancer invasiveness linked to low glucose levels - Carcinogenesis
Arsenic implicated in etiology of cancer - Diagnostics
Br-76-1 proposed as potential PET radiotracer for imaging solid tumors - Adenovirus Pathogenesis
Adenovirus type 2 and type 5 E1A genes are expressed at different levels - Adverse Drug Reaction
Cantharidin-induced cytotoxicity in the bladder linked to cyclooxygenase 2 expression - Adverse Drug Reaction
Chronic exposure of tumor cells to PD98059 decreased inhibitory effect - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
